Jérôme Dauba

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim Fizazi, Florence Joly et al. · The Lancet Oncology · 2013 · 740 citations

Medicine, Oncology, Urology +16

Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial

Élisabeth Quoix, Gérard Zalcman, Jean-Philippe Oster et al. · The Lancet · 2011 · 575 citations

Medicine, Geriatric Medicine, Oncology +10

Predictors of Early Death Risk in Older Patients Treated With First-Line Chemotherapy for Cancer

Pierre Soubeyran, Marianne Fonck, C. Blanc-Bisson et al. · Journal of Clinical Oncology · 2012 · 424 citations · Full text

Medicine, Geriatric Medicine, Oncology +17

Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018

Florian Guisier, Catherine Dubos‐Arvis, F. Viñas et al. · Journal of Thoracic Oncology · 2020 · 296 citations · Full text

Medicine, Molecular Medicine, Oncology +17

A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)

Hervé Bonnefoi, Thomas Grellety, Olivier Trédan et al. · Annals of Oncology · 2016 · 281 citations · Full text

Medicine, Oncology, Pharmacology +17